News

Brokers have retained ‘Buy’ rating on Onconova Therapeutics (NASDAQ: ONTX). The mean price target on the stock is US$ 7.5. Onconova announced commencement of its drug trial.

Brokers have revised their ratings on Fabrinet (NYSE: FN) post the announcement of its results for Q3 FY23. The consensus price target on the stock was US$ 122, which is 24.06% higher than its closing price of US$ 93.8 on May 23, 2023.

Brokers have retained their ‘Buy’ rating on Disc Medicine (NASDAQ: IRON). The consensus price target on the stock was US$ 40.75, which is 20.56% higher than its closing price of US$ 33.8 on May 19, 2023.

Brokers have given ‘Buy’ rating on Perion (NASDAQ: PERI). The consensus price target on the stock was US$ 38.81 as on Monday, May 16, 2023, according to data available on Refinitiv.

Brokers have given ‘Buy’ rating on Playa Hotels (NASDAQ: PLYA). The consensus price target on the stock was US$ 13.33 as on Thursday, May 11, 2023, according to data available on Refinitiv.

Brokers have given ‘Buy’ rating on Ventas Inc. (NYSE: VTR). The consensus price target on the stock was US$ 52.17 as on Wednesday, May 10, 2023, according to data available on Refinitiv.

Brokers have given a 'Buy' rating to U.S. Bancorp (NYSE: USB) as the company released its Q1 2023 financial reports. The consensus mean price target on the stock is US$ 44.23, which marks an upside potential of 48.72% over its closing price of US$ …